Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.69 |
| ▸ | EBP | Q15125 | 3/20 | 0.66 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.66 |
| ▸ | EBPL | Q9BY08 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360466 | 1.00 | SIGMAR1 (0.72) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL2360468 | 1.00 | SIGMAR1 (0.72) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL13366481 | 0.85 | SIGMAR1 (0.51) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL25358487 | 0.83 | SIGMAR1 (1.00) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL11684907 | 0.83 | SIGMAR1 (0.70) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL11870073 | 0.81 | SIGMAR1 (0.48) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL25358883 | 0.81 | SIGMAR1 (0.74) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL25357939 | 0.81 | SIGMAR1 (1.00) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL11864088 | 0.80 | SIGMAR1 (0.54) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| [18F]Fluspidine SCHEMBL29873189 | 0.80 | SLC18A3 (1.00) | SIGMAR1OPRM1OPRK1OPRD1EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664216-B2 | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2356123-B1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2010054961-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | SIGMAR1 123/4885ADRA2A 35/4885OPRM1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.